Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) in Australia has revised its previous advice (WHO Pharmaceuticals Newsletters No.3, 2002 and No.1, 2003) relating to grapefruit juice interactions. The committee notes that, although there have been no reports of significant clinical problems occurring when grapefruit juice and medication ingestion are separated by more than a few hours, grapefruit juice has the potential to have an interacting effect for up to 3 days after ingestion. ADRAC now considers that "the safest course is to avoid grapefruit and its juice altogether when taking medicines that interact". Statins and calcium channel blockers are some of the classes of drugs reported to interact with grapefruit juice.

Reference:

Australian Adverse Drug Reactions Bulletin 22: 8, Apr 2003.